Jun. 27 at 4:22 PM
$TVRD POSner linkedin, ("The man that kept saying "there was a great unmet need for korsuva") what a joke!
In our industry, we follow the science and act on the data. At Cara, we earned FDA approval for KORSUVA, an IV formulation of difelikefalin for patients on dialysis suffering from chronic pruritus. We also studied oral formulations of difelikefalin in several other potential indications, and all early- and mid-stage trials showed a positive signal. Unfortunately, pivotal studies across different indications did not show a meaningful clinical benefit versus placebo, compelling our board to look for strategic alternatives. All of this news followed a confounding commercial launch for IV KORSUVA, which faced unique dialysis market dynamics and ultimately weak government reimbursement. In the deal, we worked to maintain the possibility this drug would remain available to patients through leading dialysis providers with whom we’d secured strong relationships.
